KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Operating Margin (2016 - 2025)

Historic Operating Margin for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to 61.51%.

  • Halozyme Therapeutics' Operating Margin rose 52600.0% to 61.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 59.33%, marking a year-over-year increase of 89800.0%. This contributed to the annual value of 54.32% for FY2024, which is 136100.0% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Operating Margin stood at 61.51% for Q3 2025, which was up 52600.0% from 62.15% recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Operating Margin high stood at 68.19% for Q2 2021, and its period low was 22.35% during Q2 2022.
  • Moreover, its 5-year median value for Operating Margin was 53.44% (2025), whereas its average is 50.84%.
  • Its Operating Margin has fluctuated over the past 5 years, first skyrocketed by 697000bps in 2021, then plummeted by -458300bps in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Operating Margin (Quarter) stood at 55.42% in 2021, then decreased by -26bps to 41.05% in 2022, then rose by 7bps to 43.92% in 2023, then skyrocketed by 34bps to 58.89% in 2024, then increased by 4bps to 61.51% in 2025.
  • Its Operating Margin was 61.51% in Q3 2025, compared to 62.15% in Q2 2025 and 53.44% in Q1 2025.